Merck & Co. lifts 2026 outlook, Keytruda and vaccines drive shares on Wall Street

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 07:02.

Merck & Co., Inc. (US58933Y1055) updated its medium-term financial targets at a recent investor day, raising its 2026 sales and earnings ambitions on the back of oncology and vaccines strength, as detailed in its R&D and business outlook presentations. Trading on the NYSE, the U.S. pharma major highlighted a robust growth algorithm supported by cancer drug Keytruda and a broad late-stage pipeline in its latest investor materials. Merck & Co. 2026 financial outlook presentation

What Merck told investors

At its most recent R&D and business outlook day, Merck & Co., Inc. presented a higher 2026 revenue and earnings ambition, signaling confidence in the durability of Keytruda and the contribution from its vaccines and animal health businesses. Management framed the 2026 outlook around continued double-digit growth in oncology and disciplined capital allocation. Reuters coverage of Merck's long-term guidance

The company emphasized that its late-stage pipeline, including next-generation oncology agents and vaccines, is expected to support revenue beyond the U.S. patent expiry of Keytruda in the early 2030s, with management pointing to multiple Phase 3 readouts over the coming years. Merck also reiterated its focus on bolt-on acquisitions to supplement internal research, while maintaining an investment-grade balance sheet and a progressive dividend policy.

How analysts view the Merck stock

Sell-side analysts broadly welcomed the updated 2026 outlook, arguing that the clarified growth trajectory reduces uncertainty around Merck & Co.'s dependence on Keytruda and supports current valuation levels in the S&P 500 healthcare segment. Several houses highlighted that the improved guidance helps to bridge the gap to long-term consensus, which had already assumed robust oncology growth. Morningstar commentary on Merck's valuation

Analysts at large investment banks, including Goldman Sachs and JPMorgan, underline that Merck remains one of the key large-cap pharma names with visible growth into 2026, citing high-margin specialty products and an expanding vaccines franchise as differentiators versus peers such as Pfizer and Bristol Myers Squibb. Consensus estimates compiled by market data providers show a trend of gradual upward revisions to Merck's 2025 and 2026 earnings per share forecasts following the outlook update.

The product behind Merck's revenue growth

Merck & Co. generates a significant share of its revenue from the immuno-oncology therapy Keytruda, which is approved for multiple cancer indications and continues to show strong demand worldwide. Alongside Keytruda, vaccines such as Gardasil contribute materially to the company's global sales base.

Where the stock trades today

Merck & Co., Inc. shares last closed at 128.40 USD on the NYSE, based on end-of-day data on 2026-06-25.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.